Heterotandem acyclic peptide complex
The heterotandem acyclic peptide complex addresses the challenge of simultaneous targeting immune and cancer cells by binding to CD137 on immune cells and EphA2 on cancer cells, enhancing immune activation and inducing tumor cell death.
Patent Information
- Application Number
- KR1020207031802
- Authority / Receiving Office
- KR · KR
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2018-12-21
- Filing Date
- 2019-04-02
- Publication Date
- 2026-07-21
- Estimated Expiration
- 2039-04-02
AI Technical Summary
Existing cancer therapies lack effective and specific targeting mechanisms to simultaneously engage both immune cells and cancer cells, limiting their ability to induce targeted immune responses against tumors.
A heterotandem acyclic peptide complex is developed, comprising a first peptide ligand that binds to a component on an immune cell, such as CD137, and a second peptide ligand that binds to a component on a cancer cell, such as EphA2, connected via a linker, forming a covalent bond with cysteine residues to create polypeptide loops on a molecular scaffold.
The heterotandem acyclic peptide complex enhances immune cell activation and induces targeted tumor cell death, cytokine release, and immune response, demonstrating efficacy in various cancer cell lines and primary human T-cell co-culture assays.